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Summary
Background: Carotid angioplasty and stenting (CAS) is increasingly being used as a treatment
alternative to endarterectomy (CEA), especially in patients aged <70 years with signiﬁcant
carotid artery stenosis. However, an in-stent restenosis (ISR) might endangering the long-term
efﬁcacy of CAS. The aim of this article was to review the current literature regarding incidence
and clinical signiﬁcance as well as predictors of in-stent restenosis.
Methods: We conducted a systematic review of the literature to identify all studies on the
abovementioned factors.
Results: 3 randomized-controlled trials comparing CAS and CEA and 13 single centre studies
fulﬁlled our inclusion criteria. The occurrence of ISR after CAS ranged from 2.7 to 33% and was
detected within the ﬁrst year in most of the studies. The clinical impact as well as the thera-
peutic consequence of ISR remains unclear, but many baseline characteristics (age, prior CEA or
radiation), procedural (insufﬁcient stent deployment, stent dimensions, inﬂammatory marker)
and follow-up factors (reduced HDL, diabetes mellitus) could be found to identify patients at
special risk for ISR. A wide heterogeneity related to the deﬁnition and their corresponding
ultrasound criteria for ISR was observed.
Conclusions: A close follow-up is suggested especially in those patients with predictors of an ISR.
The wide range of ISR ultrasound deﬁnitions urges the need for an implementation of generally
valid criteria in ISR diagnosis. Against the background of the unknown clinical signiﬁcance of
ISR and a lacking established treatment modality these ﬁndings should be taken into account
when offering CAS as a treatment alternative to CEA.
© 2012 Published by Elsevier GmbH.
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nown as a major risk factor for disabling stroke or
eath leading to enormous socioeconomic problems. The
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Open access under CC BY-NCtandard therapy for a symptomatic stenosis of the inter-
al carotid artery has been a carotid endarterectomy (CEA)
n combination with best medical treatment of concomi-
ant cerebrovascular risk factors. In recent years, carotid
ngioplasty and stenting (CAS) has widely been used as a
reatment of ﬁrst choice in many patients, despite the fact
hat the randomized controlled trials and subsequent meta-
nalyses could not prove a general superiority of CAS over
EA [1—6]. However, the results of the aforementioned tri-
ls have been interpreted very controversely resulting in
onﬂicting recommendations in various current guidelines.
-ND license.
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nClinical signiﬁcance as well as predictors of carotid in-stent
In the American guidelines, for instance, the authors con-
cluded that CAS could be used as an equivalent treatment
modality to CEA in medium risk patients with a symptomatic
carotid stenosis [7], whereas elsewhere, CEA still is advo-
cated as the ﬁrst treatment of choice [8]. Despite this
ongoing current debate, there is accumulating evidence that
a subgroup of patients aged <70 years may proﬁt from a CAS
intervention [3—5,9]. Because the clinical long-term out-
come is of crucial importance especially in younger patients,
the occurrence of an in-stent restenosis (ISR) could be one
factor endangering the long-term efﬁcacy and safety of
CAS. Unfortunately, data concerning the rate and clinical
impact of ISR during long-term follow-up are still sparse
and show conﬂicting results [3,10,11] which may in part be
attributable to different deﬁnitions of an ISR during ultra-
sound follow-up investigations [12,13].
This article brieﬂy summarizes the currently available
long-term data of randomized controlled trials comparing
CAS and CEA and of several single centre studies regarding
the incidence and clinical impact of ISR as well as clinical
predictors for ISR.
Methods
A MEDLINE search was conducted by two independent
reviewers (K.W. and J.W.) using the following keyword
searches: ‘‘carotid artery’’, ‘‘stent’’, and ‘‘restenosis’’. As
a key feature before retrieving a full text article after inves-
tigating a potentially beneﬁcial abstract, the studies had to
fulﬁl the following criteria: (1) studies had to be published
between January 2000 and October 2011 in a journal which
is indexed within the MEDLINE database, (2) the follow-up
of the patients had to be performed for at least six months,
(3) the occurrence of carotid in-stent restenosis had to be
mentioned within the text, (4) articles had to be written in
English and (5) at least 100 stented carotid arteries had to be
investigated. If there was more than one publication about
the same patient cohort, the most recent one or rather the
publication with the longest follow-up time was used.
After retrieving the full-text article of abstracts which
met the above mentioned criteria, the following data, if
available, were extracted in a predeﬁned data sheet: (1)
number of arteries that were treated by CAS, (2) follow-up
time, (3) baseline characteristics of patients (age, propor-
tion of male patients), (4) amount and deﬁnition of ISR, (5)
clinical complications of ISR, divided into stroke and death
and (6) clinical factors which had been identiﬁed to predict
the occurrence of an ISR during follow-up. After all relevant
data had been extracted by the two reviewers, disagree-
ments were resolved by consensus with the help of a third
independent investigator (K.G.)
Results
We could identify 3 randomized, controlled studies (CAVATAS
[14,15], SPACE [1,16] and EVA-3S [2,17]) and 13 [18—30]
smaller single centre studies that fulﬁlled our inclu-
sion criteria and reported incidence, clinical signiﬁcance
and predictors of recurrent in-stent stenosis after stent-
protected angioplasty of signiﬁcant internal carotid artery
stenosis.
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etailed description of randomized trials of CAS
ersus CEA
arotid and Vertebral Artery Transluminal Angioplasty
tudy (CAVATAS) [14,15] was the ﬁrst completed, prospec-
ive multicentre trial (24 centres in Europe, Australia and
anada) comparing endovascular versus surgical treatment
f patients with symptomatic (96.4%) and asymptomatic
arotid artery stenosis. CEA was performed in 253 patients,
hereas 251 patients received endovascular treatment
mainly angioplasty alone). This study excluded high-risk
atients, and stents were used selectively, when available,
nd in only 26% of cases (n = 55). During a median carotid
ltrasound follow-up time of 4 years patients undergoing
ndovascular treatment were found to suffer signiﬁcantly
ore often from severe restenosis (≥70%) or occlusion than
atients after CEA [15]. When comparing balloon angioplasty
lone to angioplasty and stenting, those patients who were
reated with a stent (n = 50) had a signiﬁcantly lower risk of
eveloping restenosis of ≥70% (adjusted hazard ratio 0.43,
.19—0.97; p = 0.04). Regarding the clinical complications
n patients with a restenosis, the incidence of ipsilateral
troke or transient ischemic attack was signiﬁcantly higher
n patients with a restenosis ≥70% (cumulative 5-year inci-
ence 22.7% vs. 10.9%, p = 0.04) compared to those with no
SR. Current or past smoking turned out to be independently
ssociated with a higher incidence of restenosis [15].
The Stent-Supported Percutaneous Angioplasty of the
arotid Artery vs. Endarterectomy Trial (SPACE) assessed
on-inferiority of CAS to CEA and randomized 1183 patients
CAS n = 605; CEA n = 595) with a symptomatic carotid artery
tenosis as assessed with duplex ultrasound (≥50% accord-
ng to NASCET criteria, or ≥70% according to ECST criteria)
t 35 centres in Austria, Germany and Switzerland [1]. The
ype of stent and use of a protection system were chosen
t the discretion of the interventionalist. Restenosis during
ollow-up were observed more frequently in those patients
reated with CAS (4.6% vs. 10.7%, p < 0.001) compared to
EA [16]. The majority of the recurrent stenosis occurred
ithin the ﬁrst 6 months after the initial treatment (CAS
= 28 (51.9%), CEA n = 12 (52.2%)). Furthermore, additional
ew ISR were observed even after 24 months of follow-up
fter carotid stenting whereas no new recurrent restenosis
as found after CEA beyond 2 years of follow-up. Because
predeﬁned deﬁnition of ISR was not used during the study
eriod and the deﬁnition of an ISR depends on the local cri-
eria of each center, a slight overestimation of ISR might be
ossible [16].
Endarterectomy versus angioplasty in patients with
ymptomatic severe carotid stenosis (EVA-3S) trial [2] was
arried out to demonstrate non-inferiority of CAS compared
ith CEA and enrolled 527 patients with ≥60% symptomatic
arotid stenosis at 30 centres in France. In 507 patients
CAS n = 242, CEA n = 265) serial long-term carotid ultrasound
ollow-up was performed during a mean follow-up time of
.1 years [17]. Although the development of a moderate
tenosis (≥50—69%) within 3 years was found to differ sig-
iﬁcantly between the groups with a higher proportion after
AS compared to CEA (12.5% vs. 5.0%, p = 0.02), the inci-
ence of a high-grade restenosis ≥70% showed no signiﬁcant
ifference between the two groups (3.3% vs. 2.8%). A clin-
cal impact of an ISR on ipsilateral stroke or death during
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ollow-up could not be observed. Advanced age was a clini-
al risk factor, which could be identiﬁed to be predictive for
eveloping carotid restenosis [17].
To date, to the best of our knowledge, no data about
ates of restenosis have yet been published by the other
ommonly known large randomized controlled studies com-
aring CEA and CAS especially the International Carotid
tenting Study (ICSS) [31], the Carotid Revascularization
ndarterectomy vs. Stenting Trial (CREST) [4], and the Stent-
ng and Angioplasty with Protection in Patients at High Risk
or Endarterectomy study (SAPPHIRE) [11,32].
Within the analysed non-randomised trials, there was a
ide range concerning the amount of treated patients. The
mallest study included 100 patients [33]; the largest num-
er of CAS patients was enrolled in the study of Setacci et al.
n = 814) [25]. In the vast majority, patients aged 60 years or
ver with roughly two-thirds male sex were included in the
eviewed studies. The relevant data which were extracted
re delineated in Table 1. The diagnostic tool used to detect
n ISR was serial duplex ultrasound in all studies (n = 13). A
onﬁrmatory diagnostic procedure such as CTA or conven-
ional angiography had been carried out after ultrasound
n ten studies [19,21—27,29,30]. Notably, there was a wide
ariation concerning the ultrasound criteria applied for the
etection of an ISR between the studies. As one of the
ain key features for the detection of a restenosis, a cut-
ff peak systolic velocity is mentioned [19,22,24,26,28—30]
ometimes in addition to other criteria such as end-diastolic
elocity or the ICA/CCA index [18,20,21,23,25,27].
Although the minority of the studies reported concise
etails about the exact time point of ISR occurrence, most
SR were found to occur within the ﬁrst year (median: 8
onths, IQR: 7—9) after CAS [16,18,20,21,26,29,30]. There
as a broad range concerning the clinical complications for
atients with ISR between 0% [21,22,24,26,29] and 25% [30]
or stroke and from 0% [19,21—23,25,26,29] to 11.1% [18]
or death, respectively.
Common baseline characteristics like advanced age [19],
emale gender [19], prior revascularization treatment,
23,25,27,34,35] the treatment of a radiogenic stenosis [23]
r prior neck cancer [21] could be found to be predictive
or ISR development. Furthermore, some cardiovascular risk
actors such as smoking [17], lowered HDL cholesterol, [26]
iabetes mellitus [22] or elevated HbA1c [18,36] could be
dentiﬁed as predictors for ISR, too. In addition to tradi-
ional cardiovascular risk factors, periprocedural elevated
nﬂammatory markers were found to play a major role in
SR development [20,30]. Finally, several procedure-related
actors such as stent dimensions [30], implantation of multi-
le stents [19,28], or an insufﬁcient dilatation effect of CAS
19,20,28] could be identiﬁed to promote ISR.
iscussion
ecurrent stenosis after CEA was ﬁrst described by Stoney
nd String in 1976 [37] and turned out to be associated with
higher rate of periprocedural complications during a sec-
ndary operation [9]. Soon after CAS had received broader
cceptance as a potential alternative treatment option for
atients with severe carotid artery stenosis, ﬁrst reports
bout ISR were published in the late 1990s [38—40]. Since
p
a
nK. Wasser et al.
hen, the awareness for detecting an ISR has increased fur-
her and was more frequently considered in published case
eries. Within one of the most recent meta-analyses, a 180%
ncrease in the risk of intermediate to long-term carotid
estenosis was observed after CAS as compared to CEA. [41]
ince CAS is currently widely used as a treatment alterna-
ive to CEA, it is necessary to contribute to the ongoing
ontroversial discussion regarding the incidence, clinical sig-
iﬁcance and appropriate therapeutic management of ISR in
rder to ameliorate long-term efﬁcacy.
With regard to the etiology of ISR, there may be some sim-
lar mechanisms to recurrent stenosis after coronary artery
tenting. First of all, an endothelial injury which is caused
.g. by balloon inﬂation and stent placement, seems to
lay a major role for the developing of ISR, both after
AS or coronary artery stenting. This damage could initi-
te a cascade of inﬂammational processes, which ﬁnally
eads to a neointimal proliferation and a concentric ves-
el lumen reduction. Like Schillinger et al. [20] we were
ecently able to support the notion of an inﬂammatory cas-
ade as a main cause for ISR by showing that elevated
eriprocedural inﬂammation markers are signiﬁcantly cor-
elated with the development of an ISR [30]. The initial
njury of the endothelial layer caused by balloon inﬂation,
uide-wire manipulation or stent placement might explain
hy additional procedural factors could be identiﬁed within
ur literature review to inﬂuence the occurrence of ISR: the
se of multiple stents during CAS [19,28] or even wider and
onger stent dimensions by their own [30] could be identi-
ed to be associated with a higher incidence of ISR. Potential
ndothelial injuries by either an ampliﬁed sheer force of the
tent, a more pronounced abrasion or higher inﬂation pres-
ure during the procedure are some of the discussed issues
ccountable for restenosis.
Despite the heterogeneity of the analysed studies, one
f the most common ﬁndings was the time during which
n ISR could be detected as it seems to develop most
requently within the ﬁrst year after a CAS intervention
16,18,20,21,26,29,30]. This fact suggests the assumption
hat rather an intimal hyperplasia than an atherosclerotic
urden is the main driven pathologic factor for an early
estenosis.
Although different diagnostic tools and criteria were cho-
en to determine the presence of an ISR, the incidence is
urprisingly constant throughout most of the publications
nder review. The rate of moderate (≥50%) and high-grade
SR (≥70%) varies between 6.7—13.9% and 2.7—6.3%, respec-
ively (see Table 1). Notably, this rate is higher as compared
o those with a preceding CEA treatment within some of
he randomised trials [16,42], which has led to a keen
iscussion on the long-term durability of a CAS procedure
10]. Against the background that there is no established
reatment standard for patients with an ISR, this should be
onsidered before a CAS intervention is recommended as the
referred treatment modality. The surgical treatment of an
SR remains an exception since it is technically demanding
nd might be associated with periprocedural complications
43]. In most of the cases, a redo-PTA or CAS is currently
erformed after ISR, which seems to be associated with an
cceptable rate of periprocedural complications [29,30,35].
As a method of ﬁrst choice to diagnose ISR, preferably a
on-invasive technique should be chosen to avoid a potential
Clinicalsigniﬁcance
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Table 1 Main characteristics of all studies included.
First author (year) Mean follow-up
time [mo], range
Number of treated
arteries, male
patients
Mean age
(years)± SD
Deﬁnition of ISR,
DUS criteria (cm/s)
Proportion of ISR
(%) during
follow-up
Time to detection
of ISR [months]
Complications of
ISR-patients (%)
during follow-up
Independent
predictors of ISR
Willfort-Ehringer (2002) 12b, 6—24a 303, 70% 70± 9 ≥70% ICA/CCA >4 3.0 <12 Stroke 22.2 Death
11.1
Elevated HbA1c at
baseline
Khan (2003) <12, n.g. 209, 71% 72% >75 ≥50% PSV≥ 140 6.7 n.g. Stroke 0.4 Death
0.0
Age >75 y
Female gender
Multiple stent
deployment
Suboptimal CAS
result
Schillinger (2003) 6, n.g. 108, 68% ISR 62, r60-76
N-ISR 70, r65-76
≥50% PSV≥ 150
+ICA/CCA >2.5
13.9 ≤6 Stroke 13.3 Death
6.7
Prior CAS
Suboptimal CAS
result
Elevated CRP after
CAS
Skelly (2006) 5b, 0—30 109, 55% 70± 9 ≥60% PSV≥ 170
≥80%
≥60% + EDV
≥ 145
≥60% 11.0
≥80% 4.6
≥60% 7
≥80% 7, r 1—9
ISR ≥60%
Stroke 0
Death 0
Prior neck cancer
Lal (2007) 19.3, n.g. 255, n.g. ISR 71.8 ≥40% PSV≥ 140 33.3 n.g. Stroke 0.0
Death 0.0
Diabetes mellitus
Worsening of
suggested ISR
pattern
Younis (2007) 24, 6—99 399, 67% 70± 3.5 ≥80% EDV-ICA/CCA
>5.4
3.8 24.5 r 5—90 Stroke 20.0
Death 0.0
Prior CEA
Radiogenic
stenosis
AbuRahma (2008) 20, 1—78 144, 51% 70, r 40—88 ≥50%
PSV≥ 224 cm/s
≥80%
PSV≥ 325 cm/s
≥50% 7.6
≥80% 5.6
n.g. ISR ≥50%
Stroke 0.0
Death n.g.
n.g.
Setacci (2008) 45, 0—73 814, 64% 73± 8 ≥50% PSV≥ 175
≥70% PSV≥ 300,
EDV≥ 140
≥50% 9.0
≥70% 2.7
n.g. ISR ≥70%
Stroke 9.0
Death 0.0
Prior CEA
Topakian (2008) 12, n.g. 102, 66% 66± 9 ≥50%
PSV≥ 180 cm/s
9.8 ≤12 Stroke 0.0
Death 0.0
Postprocedural low
HDL cholesterol
Zhou (2008) 32, 6—48 282, n.g. 69, r 55—87 ≥70% PSV≥ 125,
EDV < 140
6.3 n.g. Stroke 11.1
Death n.g.
Prior CEA
Cosottini (2010) 26b, 0—99 200, 74% 72± 8 ≥50%
PSV≥ 220 cm/s
11.5 n.g. Stroke 13.0
Death 8.7
Suboptimal CAS
result
Multiple stent
deployment
Takigawa (2010) 28.6, 12—67 113, 86% 70± 7 ≥50%
PSV≥ 150 cm/s
11.3 9± 3 Stroke 0
Death 0
Cilostazol
Wasser (2011) 33.4b, 15—54a 210, 72% 68b ± 10 ≥70%
PSV≥ 300 cm/s
5.7 9b, 3—17a Stroke 25.0
Death 8.3
Leukocyte count
after CAS
Stent length
Stent width
DUS, duplex ultrasound; PSV, peak systolic velocity; EDV, end diastolic velocity; ICA/CCA, index of PSV of ICA and CCA; NISR, group of patients without ISR
r, range; n.g., not given.
a Interquartile range.
b Median.
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arm for the patient during the essential long-term follow-
p. In this context, serial duplex ultrasound investigations
eem to best fulﬁl the requirements for long-term follow-up
nd have been used in all studies retrieved for the cur-
ent review. As a secondary validation method, high-grade
SR could be conﬁrmed by CT angiography in some selected
ases. Since duplex ultrasound has turned out to lead to
reliable ISR diagnosis whereas conventional angiography
s known to be an invasive procedure possibly linked with
otentially dangerous complications such as stroke or bleed-
ngs, a conventional angiography should only be considered
n those patients with a symptomatic or high-grade ISR, who
re likely to be treated afterwards or within the same angio-
raphic session.
A fact which could reduce the value of duplex ultrasound
s a ﬁrst choice method for serial follow-up investigations
s the generally lacking agreement of exact ultrasound cri-
eria to grade an ISR. Considering the peak systolic velocity
PSV) as the most commonly used duplex criterion, a con-
iderable distribution of cut-off values could be observed.
or example, the cut-off PSV for the diagnosis of an ISR
f ≥50% varied from ≥140 cm/s in one study [19], over a
SV≥ 175 cm/s in the publication of Setacci et al. [25] and
PSV≥ 220 cm/s in the study by Cosottini et al. [28] up to
PSV≥ 224 cm/s by AbuRahma et al. [24]. Despite the fact
hat ultrasound criteria have to be adapted to each local
igh quality ultrasound laboratory, the wide range of values
etween the studies urges the need for an implementation
f generally valid ultrasound criteria in ISR diagnosis [12,13].
There is currently a very controversial discussion on the
linical impact of ISR. Amongst others, the results from the
PACE study have encouraged those claiming that resteno-
is might be a relatively benign pathology [16,44]. On the
ther hand, especially long-term follow-up data raise con-
ern that patients with ISR could be suffering from a higher
omplication rate in comparison to patients without ISR [30].
ince CAS is often recommended the treatment of choice in
ounger patients (<70a) [3—5,9] it is of greatest interest to
valuate the complication rates of ISR in the long run. By
ow, the results regarding the incidence and clinical compli-
ations of ISR of the randomized controlled trials comparing
AS and CEA [4,6,11] are eagerly awaited.
The unresolved clinical impact of ISR further highlights
he importance to identify independent risk factors which
re predictive for an ISR. These would be helpful to detect
hose patients in which a tight follow up is necessary.
dvanced age [17,19] has been found to be predictive for an
SR, which would further contribute to the recommendation
f choosing a CEA as a ﬁrst treatment of choice especially
n elderly patients [3,5]. CAS is frequently recommended
n patients with a restenosis after CEA because a redo-CEA
ometimes appears to be technically difﬁcult and might bear
higher periprocedural risk than the initial operation [7] or
n patients with a radiogenic stenosis [45]. When considering
he optimal treatment option for those patient subgroups,
ne should take into account though that a CAS procedure
ecause of a CEA-restenosis or radiation-induced stenosis is
lso associated with a higher rate of ISR [20,23,34,35]. An
nsufﬁcient result after a CAS procedure, e.g. due to insuf-
cient stent adaptation, could be shown to be associated
ith a higher risk of ISR occurrence [19,20,28]. Therefore, to
meliorate the long-term beneﬁt of a CAS, it is a worthwhileK. Wasser et al.
im to pursue a perfect stent adaptation to the vessel lumen.
he fact that an aggressive postdilation bears the risk of dis-
al embolization and microvascular injury, which may itself
nitiate neointimal hyperplasia complicates the procedure.
urthermore, the characteristics of the stent deployed are
f special interest regarding the incidence of ISR. Usually,
he selection of the stent length and width are based on
ngiographic ﬁndings in order to appropriately cover the
tenosis. However, narrower and longer stents were corre-
ated with a higher ISR risk [28,30]. It is conceivable that
stent with a larger diameter results in a reduced ﬂow-
elocity, less turbulences and thus in less frequent ISR. A
onger stent, which is used to cover longer lesions, proba-
ly represents the presence of a high plaque burden and has
epeatedly been identiﬁed as an independent predictor for
eriprocedural complications [46,47]. Although it is clear
hat mainly anatomical conditions lead to the selection of a
peciﬁc stent, it is recommendable to choose the shortest
ut widest stent as possible in order to minimize the risk of
SR development and to closely follow-up those patients in
hom a longer, narrower stent has been used.
After a successful CAS, a stringent monitoring of cardio-
ascular risk factors seems to be essential. Not only with
egard to primary and secondary stroke prevention, but
lso especially in the context of ISR development, several
ublications show a correlation between the presence of
ardiovascular risk factors, such as tobacco use [17,42],
iabetes mellitus [18,22], e.g. represented by an elevated
bA1c [36], low HDL cholesterol [26], and the occurrence of
n ISR.
onclusions
SR after CAS is frequently observed within the ﬁrst year
f follow-up and might be associated with a higher risk for
linical complications. Against the light that a CAS interven-
ion is frequently recommended as an alternative treatment
trategy to CEA especially in patients aged <70 years, a
ight and long-lasting follow-up is warranted. Particularly
atients who are of advanced age, treated for a radio-
enic stenosis or a recurrent stenosis after CEA, or with
he presence of cardiovascular risk factors such as tobacco
se, diabetes mellitus or a dyslipoproteinemia or certain
rocedure-related factors (a narrow or long stent, insuf-
cient stent adaptation after CAS or the use of multiple
tents) are prone to develop an ISR. A signiﬁcant hetero-
eneity especially regarding the exact duplex criteria to
dentify an ISR has been observed between the reviewed
tudies thus supporting the need to establish commonly
ccepted criteria for ISR-grading. With respect to the pos-
ible clinical relevance of an ISR and a lacking commonly
ccepted treatment strategy, all efforts should be made to
arefully follow-up especially those patient subgroups at risk
or ISR in order to further develop an optimized treatment
trategy.
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